West Declares Quarterly Dividend

West Declares Quarterly Dividend
Bacakan Artikel

EmitenTrust.com EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026.

About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life saving and life enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. 

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 

Media Contact:

Michele Polinsky

Vice President, Global Communications

+1-610-594-3054

Michele.Polinsky@westpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-declares-quarterly-dividend-302913197.html

SOURCE West Pharmaceutical Services, Inc.

Artikel ini dipublikasikan ulang secara utuh melalui program kemitraan media dengan prnewswire.com. Seluruh isi materi, data, dan sudut pandang editorial sepenuhnya merupakan tanggung jawab redaksi penerbit asli.